FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Executive Summary
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
You may also be interested in...
FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement
Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.
FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.